Our vision

Where technology meets healthcare

About us

Our mission

Our goal is to vastly improve patient care and outcomes by bringing innovative eyecare technology to the healthcare industry. We want to significantly advance the efficacy and safety of existing eyecare drugs, while developing new ophthalmic drugs that address many unmet medical needs.

Through our unique and extensive partnerships, we are able to identify and launch new technologies into beneficial treatments that can help many patients worldwide.

our Product pipeline

IC265 Potent syk kinase inhibitor

  • Phase II Proof of Concept completed Q1 2018 using conjunctival allergen challenge model
  • Positive anti-inflammatory activity demonstrated with impressive effects on hyperemia v. olopatadine (antihistamine) and prednisolone (steroid)
  • Ready for Phase II study in dry eye
  • The global dye eye disease market is projected to rise from US$ 5.0B in 2016 to US$ 7.8B by 2025

IC270 Antihistamine plus IC265

  • Patient surveys suggest that a substantial portion of the allergic conjunctivitis population is unsatisfied with current treatment options
  • In a Phase 2 conjunctival allergen challenge model, IC265 was more effective than vehicle and Patanol (market leading ocular allergy product) in reducing redness when dosing 8 hours prior to administration of allergy challenge
  • The ability to treat itch (by combining it with a commercially approved antihistamine) as well as redness/inflammation could significantly differentiate it from other leading marketed products

IC800 Dual ENKephalinase inhibitors (DENKI®)

  • Only limited effective local ocular analgesics are currently available to treat ocular pain. Oral opioids are currently prescribed for severe eye pain
  • IC800 is a novel non-opioid mechanism of action for the treatment of pain
  • Demonstrated efficacy in pharmacology and preclinical animal studies
  • Potentially more effective than Steroids and NSAIDs without the safety concerns and issues
  • IC805 is the DENKI technology optimized for acute post-surgical pain

DENKI® is a registered trademark of Pharmaleads SA.

With a resolute emphasis on knowledge-based innovation, proven skills of individuals and unique partnerships, I think we are witnessing a new era in ophthalmic products.

Steve Johnson

Chief operating Officer

steps to success and milestones

Invest in our Future

We are currently exploring partnerships and development opportunities that would support the development and commercialization of our pipeline products.

acquired technology

We have acquired rights to multiple products since our inception in 2016.

Begin Clinical trials

We plan to initiate clinical trials for both IC265 and IC270 in 2021. Both IC800 and IC805 are being developed and prepared for an IND.

Completed

Currently pursuing

on the horizon

The IACTA team

Cultivating IACTA's vision with leadership, experience, and insight

leadership

Damon Burrows

Founder / Chief Executive Officer

Damon is an experienced Pharmaceutical Executive with 20 years experience working in the life sciences and healthcare industries. He has experience in large and small pharmaceutical companies and has successfully navigated numerous drug development programs through the FDA regulatory approval process and commercial launch. He has extensive Public Policy experience and has worked with numerous Federal and State Agencies on the Regulatory challenges of commercialization.

Stephen Johnson, Hon BSC, MBA

Chief Operating Officer

Steve has 30+ years of demonstrated success in the pharmaceutical/biotech and medical device industries. He has held various executive leadership and management positions within R&D and has lead numerous global Rx, OTC, and device projects.

Prior to joining IACTA, Steve provided his expertise to pharmaceutical and device companies as a Management Consultant. He used is cumulated knowledge of portfolio management, project management, strategic planning, clinical operations, IT, QC/QA, biostatistics, and data management to help develop a number of new technologies.

Steve has also held various executive positions at Allergan Inc. for over 18 years. He served as a member of the R&D executive governance committees whose responsibilities included the successful development and global registration of key products, as well as the oversight of projects, budgets, facilities, human capital, and R&D productivity.

Steve has a Masters in Business Administration from the University of Missouri and an Honors Degree in Biochemistry and Pharmacology from the University of Western Ontario.

Orest Olejnik, PhD, FRPharmS

Chief Scientific Officer

Orest has more than 35 years of product development experience, covering both small and large molecules, including novel ocular drug delivery systems, within the pharmaceutical industry. Prior to joining IACTA, Orest was the Senior Vice President of Global Pharmaceutical Sciences at Allergan, Inc. He also held positions at Johnson & Johnson, CooperVision, and Fisons.

Orest has contributed to well over 30 regulatory submissions, representing a successfully strong track record for product approvals worldwide, with a predominant emphasis in ophthalmology. He was also a pivotal contributor and inventor covering numerous marketed products including those used in the treatment of glaucoma and dry eye.

Orest is a fellow of the Royal Pharmaceutical Society of Great Britain. He received his Ph.D. from the University of Nottingham, UK and his B.Sc. (Hons) in Pharmacy from the Sunderland School of Pharmacy, UK.

He has held academic positions, most recently as visiting professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland.

William Pedranti, JD

Founder / Chief Administrative Officer

Will is Chief Administrative Officer for IACTA.  He is a biotech entrepreneur who has co-founded several biotech companies; one of which was sold for $70 million. Will was most recently the President, Operations for Scilex Pharmaceuticals, a company which he co-founded and recently received approval for and launched a prescription non-opioid drug for the treatment of pain. Will's past experience includes working as a partner at national law firms as well as the Vice President, General Counsel and member of the Executive Committee of a publicly traded, commercial-stage biotech company that operated globally. Will has experience with oversight of all operations of a company, including commercial, R&D, finance, manufacturing, corporate governance, legal, compliance, regulatory, business development, international operations, litigation/disputes, securities and intellectual property functions.

Will earned a Juris Doctor (JD) degree in law from Georgetown University Law Center and a Bachelor of Sciences (BS) in Business Entrepreneurship from the University of Southern California.

GEORGE NG, JD

Founder / Chief Business Officer

George, Chief Business Officer for IACTA, overseeing business development, corporate development and capital raising, is a seasoned life sciences industry executive. He has founded and/or led multiple companies, including Scilex Pharmaceuticals, Inc., where he was Co-Founder and President, Business, and led the company through development, clinical trials, NDA submission, FDA approval, $140 million financing and commercial launch of the company’s first FDA-approved drug product. George has also held various other senior management positions, including Board Director, Managing Director, Chief Administrative Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded and private, global biotechnology and pharmaceutical companies, including Sorrento Therapeutics, Inc. (NASDAQ: SRNE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). In these roles, George helped lead the development and commercialization efforts and launches of multiple pharmaceutical drug products.  Previously, in private practice, George was a partner in two AMLAW 200 law firms, where he had leadership roles, including establishing the life sciences practice group for one firm and heading it as the national co-chair. Additionally, George is a current member of the Board of Directors for multiple companies, including Morphogenesis, Inc. and Calidi Biotherapeutics, Inc.

George earned a Juris Doctor (JD) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (BAS) dual degree in Biochemistry & Economics from the University of California, Davis.

IACTA In the news

View our Awards, recognitions, and Press releases

Read more